Body mass index and response to infliximab in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 33, Issue 4, 2015, Pages 478-483

  Ottaviani, Sébastien ^a,b   Gardette, Anaïs ^a,b   Tubach, Florence ^a,b,c   Roy, Carine ^a,b,c   Palazzo, Elisabeth ^a,b   Gill, Ghislaine ^a,b   Meyer, Olivier ^a,b   Dieudé, Philippe ^a,b  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

Author keywords

Infliximab; Obesity; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DAS28; DISEASE ASSOCIATION; DOSE RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JOINT SWELLING; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; VISUAL ANALOG SCALE; ARTHRALGIA; ARTHRITIS, RHEUMATOID; BLOOD; COMORBIDITY; DRUG MONITORING; FRANCE; MIDDLE AGED; PAIN MEASUREMENT; PATHOPHYSIOLOGY; PATIENT ACUITY; PROCEDURES; RISK FACTOR;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRALGIA; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; BODY MASS INDEX; C-REACTIVE PROTEIN; COMORBIDITY; DRUG MONITORING; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; OBESITY; PAIN MEASUREMENT; PATIENT ACUITY; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939526809     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. WHO: Obesity: preventing and managing the global epidemic. Technical Report Series 2000; 894.
2. HANLEY MJ, ABERNETHY DR, GREENBLATT DJ: Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49: 71-87.
3. TILG H, MOSCHEN AR: Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-83.
4. MULLER-LADNER U, NEUMANN E: Rheumatoid arthritis: the multifaceted role of adiponectin in inflammatory joint disease. Nat Rev Rheumatol 2009; 5: 659-60.
5. STAVROPOULOS-KALINOGLOU A, METSIOS GS, KOUTEDAKIS Y, KITAS GD: Obesity in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50: 450-62.
6. NARANJO A, SOKKA T, DESCALZO MA et al.: Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008; 10: R30.
7. ARMSTRONG DJ, McCAUSLAND EM, QUINN AD, WRIGHT GD: Obesity and cardiovascular risk factors in rheumatoid arthritis. Rheumatology (Oxford) 2006; 45:782; author reply 782-3.
8. VOIGT LF, KOEPSELL TD, NELSON JL, DUGOWSON CE, DALING JR: Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology 1994; 5: 525-32.
9. SYMMONS DP, BANKHEAD CR, HARRISON BJ et al.: Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 1997; 40: 1955-61.
10. WESTHOFF G, RAU R, ZINK A: Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum 2007; 56: 3575-82.
11. van der HELM-van MIL AH, van der KOOIJ SM, ALLAART CF, TOES RE, HUIZINGA TW: A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis 2008; 67: 769-74.
12. KAUFMANN J, KIELSTEIN V, KILIAN S, STEIN G, HEIN G: Relation between body mass index and radiological progression in patients with rheumatoid arthritis. J Rheumatol 2003; 30: 2350-5.
13. ROUBENOFF R, ROUBENOFF RA, WARD LM, HOLLAND SM, HELLMANN DB: Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor. J Rheumatol 1992; 19: 1505-10.
14. KLAASEN R, WIJBRANDTS CA, GERLAG DM, TAK PP: Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 2011; 63: 359-64.
15. GREMESE E, CARLETTO A, PADOVAN M et al.: Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: An approach to a personalized medicine. Arthritis Care Res (Hoboken) 2013; 65: 94-100.
16. OTTAVIANI S, ALLANORE Y, TUBACH F et al.: Body mass index influences the response to infliximab in ankylosing spondylitis. Arthritis Res Ther 2012; 14: R115.
17. ALETAHA D, NEOGI T, SILMAN AJ et al.: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
18. SMOLEN JS, LANDEWé R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
19. FAUTREL B, PHAM T, MOUTERDE G et al.: Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine 2007; 74: 627-37.
20. van GESTEL AM, HAAGSMA CJ, van RIEL PL: Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 1845-50.
21. ADAMS KF, SCHATZKIN A, HARRIS TB et al.: Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006; 355: 763-78.
22. FLEGAL KM, CARROLL MD, OGDEN CL, CURTIN LR: Prevalence and trends in obesity among US adults, 1999-2008. Jama 2010; 303: 235-41.
23. de ROOY DP, van der LINDEN MP, KNEVEL R, HUIZINGA TW, van der HELM-van MIL AH: Predicting arthritis outcomes-what can be learned from the Leiden Early Arthritis Clinic?. Rheumatology (Oxford) 2011; 50: 93-100.
24. HEIMANS L, van den BROEK M, le CESSIE S et al.: Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2013; 65: 1235-42.
25. GREMESE E, BERNARDI S, BONAZZA S et al.: Body weight, gender and response to TNF-alpha blockers in axial spondyloarthritis. Rheumatology (Oxford) 2014.
26. di MINNO MN, PELUSO R, IERVOLINO S et al.: Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) 2013; 65: 141-7.
27. EDER L, THAVANESWARAN A, CHANDRAN V, COOK RJ, GLADMAN DD: Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis 2014.
28. NEUMANN E, FROMMER K, VASILE M, MULLER-LADNER U: Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases?. Arthritis Rheum 2011; 63: 1159-69.
29. GONZALEZ-GAY MA, LLORCA J, GARCIA-UNZUETA MT et al.: High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 596-603.
30. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, GONZALEZ-JUANATEY C et al.: Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 311-6.
31. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, BERJA A et al.: Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin Exp Rheumatol 2009; 27: 222-8.
32. GONZALEZ-GAY MA, VAZQUEZ-RODRIGUEZ TR, GARCIA-UNZUETA MT et al.: Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy. Clin Exp Rheumatol 2010; 28: 56-62.
33. BENDTZEN K, GEBOREK P, SVENSON M, LARSSON L, KAPETANOVIC MC, SAXNE T: Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006; 54: 3782-9.
34. St CLAIR EW, WAGNER CL, FASANMADE AA et al.: The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451-9.
35. KRZYSIEK R, BREBAN M, RAVAUD P et al.: Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. Arthritis Rheum 2009; 61: 569-76.
36. VILLELA NR, KRAMER-AGUIAR LG, BOTTINO DA, WIERNSPERGER N, BOUSKELA E: Metabolic disturbances linked to obesity: the role of impaired tissue perfusion. Arq Bras Endocrinol Metabol 2009; 53: 238-45.